{"transactions":[{"id":731702,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-18T22:45:15.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":15600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest in full upon the earlier to occur of the first anniversary of the date of grant, the date of the Issuer's next annual meeting or a change of control as defined in the Issuer's 2025 Equity Incentive Plan."}],"balance_after":15600,"derivative":{"exercise_price":5.45,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":15600},"source":{"system":"sec-edgar","filing":"0001555242-26-000002","document":"form4-06182026_060606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555242/000155524226000002/form4-06182026_060606.xml","form_type":"4"}},{"id":960662,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-22T22:15:33.000Z","date":"2025-12-18","kind":"grant","planned":false,"acquired":true,"shares":31200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The award was granted as an Initial Grant as contemplated by the non-employee director compensation policy adopted by the Issuer's board of directors on December 18, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests over a three-year period, with 1/36th of the shares subject to the option vesting in 36 substantially equal monthly installments, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan) through each such date."}],"balance_after":31200,"derivative":{"exercise_price":6.19,"expiration_date":"2035-12-18","underlying":"Common Stock","underlying_shares":31200},"source":{"system":"sec-edgar","filing":"0001555242-25-000005","document":"form4-12222025_101230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555242/000155524225000005/form4-12222025_101230.xml","form_type":"4"}},{"id":1065060,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-15T20:51:56.000Z","date":"2025-07-25","kind":"grant","planned":false,"acquired":true,"shares":971173,"ownership":{"direct":false,"nature":"By Engene Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of December 23, 2024, by and among, the Issuer, Insight Merger Sub I, a wholly-owned subsidiary of the Issuer (\"Merger Sub I\"), Insight Merger Sub II, a wholly-owned subsidiary of the Issuer (\"Merger Sub II\") and Inmagene Biopharmaceuticals (\"Legacy Inmagene\") (the \"Merger Agreement\"), on July 25, 2025, Merger Sub I merged with and into Legacy Inmagene (the \"First Merger\"), with Legacy Inmagene surviving the First Merger as a wholly-owned subsidiary of the Issuer, and immediately after the First Merger, Legacy Inmagene merged with and into Merger Sub II, with Merger Sub II surviving the First Merger as a wholly-owned subsidiary of the Issuer (the \"Second Merger\" and together with the First Merger, the \"Merger\"). (continued in the next footnote)."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Upon the closing of the Merger, each Legacy Inmagene ordinary and preferred share was converted into the right to receive 0.003051 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Ikena Oncology, Inc. (\"Ikena\") to ImageneBio, Inc."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Received in exchange for 318,313,306 ordinary shares of Legacy Inmagene pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of December 23, 2024, by and among, the Issuer, Insight Merger Sub I, a wholly-owned subsidiary of the Issuer (\"Merger Sub I\"), Insight Merger Sub II, a wholly-owned subsidiary of the Issuer (\"Merger Sub II\") and Inmagene Biopharmaceuticals (\"Legacy Inmagene\") (the \"Merger Agreement\"), on July 25, 2025, Merger Sub I merged with and into Legacy Inmagene (the \"First Merger\"), with Legacy Inmagene surviving the First Merger as a wholly-owned subsidiary of the Issuer, and immediately after the First Merger, Legacy Inmagene merged with and into Merger Sub II, with Merger Sub II surviving the First Merger as a wholly-owned subsidiary of the Issuer (the \"Second Merger\" and together with the First Merger, the \"Merger\"). (continued in the next footnote)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger, each Legacy Inmagene ordinary and preferred share was converted into the right to receive 0.003051 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Ikena Oncology, Inc. (\"Ikena\") to ImageneBio, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for 318,313,306 ordinary shares of Legacy Inmagene pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Engene Inc.'s sole shareholder is YJH Trust of which Trident Trust Company (HK) Limited serves as trustee. Dr. Wang's spouse and daughter are the sole beneficiaries of YJH Trust. Accordingly, Dr. Wang has an indirect pecuniary interest over the shares of the Issuer held by Engene Inc. Dr. Wang disclaims beneficial ownership of the shares held by Engene Inc. except to the extent of his pecuniary interest therein, if any."}],"balance_after":971173,"source":{"system":"sec-edgar","filing":"0001415889-25-022091","document":"form4-08152025_080852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555242/000141588925022091/form4-08152025_080852.xml","form_type":"4"}},{"id":1065059,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-15T20:51:56.000Z","date":"2025-07-25","kind":"grant","planned":false,"acquired":true,"shares":143832,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of December 23, 2024, by and among, the Issuer, Insight Merger Sub I, a wholly-owned subsidiary of the Issuer (\"Merger Sub I\"), Insight Merger Sub II, a wholly-owned subsidiary of the Issuer (\"Merger Sub II\") and Inmagene Biopharmaceuticals (\"Legacy Inmagene\") (the \"Merger Agreement\"), on July 25, 2025, Merger Sub I merged with and into Legacy Inmagene (the \"First Merger\"), with Legacy Inmagene surviving the First Merger as a wholly-owned subsidiary of the Issuer, and immediately after the First Merger, Legacy Inmagene merged with and into Merger Sub II, with Merger Sub II surviving the First Merger as a wholly-owned subsidiary of the Issuer (the \"Second Merger\" and together with the First Merger, the \"Merger\"). (continued in the next footnote)."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Upon the closing of the Merger, each Legacy Inmagene ordinary and preferred share was converted into the right to receive 0.003051 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Ikena Oncology, Inc. (\"Ikena\") to ImageneBio, Inc."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Received in exchange for 47,142,857 Series Seed convertible preferred shares of Legacy Inmagene pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of December 23, 2024, by and among, the Issuer, Insight Merger Sub I, a wholly-owned subsidiary of the Issuer (\"Merger Sub I\"), Insight Merger Sub II, a wholly-owned subsidiary of the Issuer (\"Merger Sub II\") and Inmagene Biopharmaceuticals (\"Legacy Inmagene\") (the \"Merger Agreement\"), on July 25, 2025, Merger Sub I merged with and into Legacy Inmagene (the \"First Merger\"), with Legacy Inmagene surviving the First Merger as a wholly-owned subsidiary of the Issuer, and immediately after the First Merger, Legacy Inmagene merged with and into Merger Sub II, with Merger Sub II surviving the First Merger as a wholly-owned subsidiary of the Issuer (the \"Second Merger\" and together with the First Merger, the \"Merger\"). (continued in the next footnote)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger, each Legacy Inmagene ordinary and preferred share was converted into the right to receive 0.003051 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Ikena Oncology, Inc. (\"Ikena\") to ImageneBio, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 47,142,857 Series Seed convertible preferred shares of Legacy Inmagene pursuant to the Merger Agreement."}],"balance_after":143832,"source":{"system":"sec-edgar","filing":"0001415889-25-022091","document":"form4-08152025_080852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555242/000141588925022091/form4-08152025_080852.xml","form_type":"4"}},{"id":4537922,"issuer":{"id":180768,"kind":"organization","name":"RESPONSE BIOMEDICAL CORP","symbol":"RBM"},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-01T20:41:41.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Price shown is denominated in Canadian Dollars."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of the Arrangement, out of money stock options were cancelled."}],"balance_after":0,"derivative":{"exercise_price":1.6,"exercise_date":"2013-08-13","expiration_date":"2022-08-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-16-042826","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/806888/000143774916042826/rdgdoc.xml","form_type":"4"}},{"id":4537921,"issuer":{"id":180768,"kind":"organization","name":"RESPONSE BIOMEDICAL CORP","symbol":"RBM"},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-01T20:41:41.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Price shown is denominated in Canadian Dollars."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"In connection with the Arrangement, all outstanding options to purchase common shares of the issuer as of immediately prior to the effective time of the Arrangement, were deemed  unconditionally vested and exercisable, and subsequently cancelled in exchange for cash payment equal to the difference between the per share consideration of $1.12 CDN and the per share exercise price of such option multiplied by the number of  common shares issuable pursuant to such option, less applicable withholdings."}],"balance_after":0,"derivative":{"exercise_price":0.85,"exercise_date":"2017-03-24","expiration_date":"2026-03-23","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001437749-16-042826","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/806888/000143774916042826/rdgdoc.xml","form_type":"4"}},{"id":4537920,"issuer":{"id":180768,"kind":"organization","name":"RESPONSE BIOMEDICAL CORP","symbol":"RBM"},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-01T20:41:41.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Price shown is denominated in Canadian Dollars."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"In connection with the Arrangement, all outstanding options to purchase common shares of the issuer as of immediately prior to the effective time of the Arrangement, were deemed  unconditionally vested and exercisable, and subsequently cancelled in exchange for cash payment equal to the difference between the per share consideration of $1.12 CDN and the per share exercise price of such option multiplied by the number of  common shares issuable pursuant to such option, less applicable withholdings."}],"balance_after":0,"derivative":{"exercise_price":0.92,"exercise_date":"2016-03-19","expiration_date":"2025-03-19","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001437749-16-042826","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/806888/000143774916042826/rdgdoc.xml","form_type":"4"}},{"id":4537919,"issuer":{"id":180768,"kind":"organization","name":"RESPONSE BIOMEDICAL CORP","symbol":"RBM"},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-01T20:41:41.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Price shown is denominated in Canadian Dollars."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of the Arrangement, out of money stock options were cancelled."}],"balance_after":0,"derivative":{"exercise_price":1.43,"exercise_date":"2014-03-14","expiration_date":"2023-03-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001437749-16-042826","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/806888/000143774916042826/rdgdoc.xml","form_type":"4"}},{"id":4537918,"issuer":{"id":180768,"kind":"organization","name":"RESPONSE BIOMEDICAL CORP","symbol":"RBM"},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-01T20:41:41.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Price shown is denominated in Canadian Dollars."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of the Arrangement, out of money stock options were cancelled."}],"balance_after":0,"derivative":{"exercise_price":3.1,"exercise_date":"2014-03-14","expiration_date":"2023-03-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-16-042826","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/806888/000143774916042826/rdgdoc.xml","form_type":"4"}},{"id":4537917,"issuer":{"id":180768,"kind":"organization","name":"RESPONSE BIOMEDICAL CORP","symbol":"RBM"},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2016-12-01T20:41:41.000Z","date":"2016-11-29","kind":"other","acquired":false,"shares":2149902,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the transactions contemplated by the Agreement and Plan of Arrangement by and between the issuer and 1077801 B.C. Ltd., dated June 16, 2016 (the \"Arrangement\"), the reporting person rolled over their shares of common stock of the issuer into shares of common stock of 1077801 B.C. Ltd on a one-to-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Capital, OrbiMed Advisors, Isaly, OrbiMed Advisors Limited (\"OrbiMed Limited\") and OrbiMed Asia GP, L.P. (\"OrbiMed Asia\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any entity or person, including the Reporting Person, is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These Shares and Warrants are held of record by OAP and may be deemed to be indirectly beneficially owned by OrbiMed Asia and OrbiMed Limited. OrbiMed Asia is the sole general partner of OAP and OrbiMed Limited is the sole general partner of OrbiMed Asia. As a result, OrbiMed Asia has the power to direct the vote and to direct the disposition of the securities held by OAP and such power is exercised through OrbiMed Limited."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001437749-16-042826","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/806888/000143774916042826/rdgdoc.xml","form_type":"4"}},{"id":4537916,"issuer":{"id":180768,"kind":"organization","name":"RESPONSE BIOMEDICAL CORP","symbol":"RBM"},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2016-12-01T20:41:41.000Z","date":"2016-11-29","kind":"other","acquired":false,"shares":34291,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the transactions contemplated by the Agreement and Plan of Arrangement by and between the issuer and 1077801 B.C. Ltd., dated June 16, 2016 (the \"Arrangement\"), the reporting person rolled over their shares of common stock of the issuer into shares of common stock of 1077801 B.C. Ltd on a one-to-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Capital, OrbiMed Advisors, Isaly, OrbiMed Advisors Limited (\"OrbiMed Limited\") and OrbiMed Asia GP, L.P. (\"OrbiMed Asia\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any entity or person, including the Reporting Person, is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These Shares and Warrants are held of record by OA III and may be deemed to be indirectly beneficially owned by OrbiMed Advisors and Isaly. OrbiMed Advisors is the sole general partner of OA III, and Isaly is the managing member of, and holder of a controlling interest in, OrbiMed Advisors. As a result, Isaly and OrbiMed Advisors share power to direct the vote and to direct the disposition of the securities held by OA III."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001437749-16-042826","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/806888/000143774916042826/rdgdoc.xml","form_type":"4"}},{"id":4537915,"issuer":{"id":180768,"kind":"organization","name":"RESPONSE BIOMEDICAL CORP","symbol":"RBM"},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2016-12-01T20:41:41.000Z","date":"2016-11-29","kind":"other","acquired":false,"shares":3604266,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the transactions contemplated by the Agreement and Plan of Arrangement by and between the issuer and 1077801 B.C. Ltd., dated June 16, 2016 (the \"Arrangement\"), the reporting person rolled over their shares of common stock of the issuer into shares of common stock of 1077801 B.C. Ltd on a one-to-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Shares and warrants to purchase Shares (\"Warrants\") are held of record by OPI III and may be deemed to be indirectly beneficially owned by OrbiMed Capital GP III LLC (\"OrbiMed Capital\"), OrbiMed Advisors LLC (\"OrbiMed Advisors\"), and Samuel D. Isaly (\"Isaly\"). OrbiMed Capital is the sole general partner of OPI III. OrbiMed Advisors, a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed Capital. Pursuant to those relationships, OrbiMed Capital and OrbiMed Advisors have discretionary investment management authority with respect to the assets of OPI III."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Such authority includes the power to vote and otherwise dispose of the securities held by OPI III. Isaly, a natural person, is the managing member of, and holder of a controlling interest in, OrbiMed Advisors. As a result, Isaly, OrbiMed Advisors and OrbiMed Capital share power to direct the vote and to direct the disposition of the securities held by OPI III. The Reporting Person is an employee of OrbiMed Advisors"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Capital, OrbiMed Advisors, Isaly, OrbiMed Advisors Limited (\"OrbiMed Limited\") and OrbiMed Asia GP, L.P. (\"OrbiMed Asia\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any entity or person, including the Reporting Person, is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001437749-16-042826","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/806888/000143774916042826/rdgdoc.xml","form_type":"4"}},{"id":4537914,"issuer":{"id":180768,"kind":"organization","name":"RESPONSE BIOMEDICAL CORP","symbol":"RBM"},"owners":[{"id":36707,"kind":"person","name":"Wang Jonathan Jian","position":1,"cik":"0001555242","reported_name":"Wang Jonathan Jian","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2016-12-01T20:41:41.000Z","date":"2016-11-29","kind":"other","acquired":false,"shares":71396,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the transactions contemplated by the Agreement and Plan of Arrangement by and between the issuer and 1077801 B.C. Ltd., dated June 16, 2016 (the \"Arrangement\"), the reporting person rolled over their shares of common stock of the issuer into shares of common stock of 1077801 B.C. Ltd on a one-to-one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person holds these shares of Common Stock of the Issuer (\"Shares\") on behalf of OrbiMed Private Investments III (\"OPI III\"), OrbiMed Asia Partners, L.P. (\"OAP\") and OrbiMed Associates III, LP (\"OA III\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001437749-16-042826","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/806888/000143774916042826/rdgdoc.xml","form_type":"4"}}]}